A short-term storage of stem/progenitor cells in regenerative medicine without cryopreservation and cryoprotector. The protective composition of the invention improves the quality and increases the efficiency of cell therapy by keeping stem/progenitor cells free of ultra-low temperatures (liquid nitrogen) and cryoprotectants during the period of their biosafety testing and transportation to a patient's bed.

A short-term storage of stem/progenitor cells in regenerative medicine without cryopreservation and cryoprotector. The protective composition of the invention improves the quality and increases the efficiency of cell therapy by keeping stem/progenitor cells free of ultra-low temperatures (liquid nitrogen) and cryoprotectants during the period of their biosafety testing and transportation to a patient's bed.

Described herein are compositions for use in medicine as anti-ischemic organ storage and perfusion solutions.

Embodiments of the present invention relate generally to processes, systems, and compositions useful in manipulating a ratio of viable X chromosome bearing sperm to viable Y chromosome bearing sperm in at least one sperm population and useful for preserving the resulting manipulated sperm population. In some embodiments a cryoprotectant may be incorporated into various medias used in manipulating the sperm sample, such as in a staining media, a sheath fluid, and a collection media.

Embodiments of the present invention relate generally to processes, systems, and compositions useful in manipulating a ratio of viable X chromosome bearing sperm to viable Y chromosome bearing sperm in at least one sperm population and useful for preserving the resulting manipulated sperm population. In some embodiments a cryoprotectant may be incorporated into various medias used in manipulating the sperm sample, such as in a staining media, a sheath fluid, and a collection media.

A lung perfusion solution comprises a base solution comprising a physiological mixture of electrolytes and buffers, 3.5-5.5% (w/v) a first macromolecule having a molecular weight of 40-100 KDa, and an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to 2.0-3.0.

A lung perfusion solution comprises a base solution comprising a physiological mixture of electrolytes and buffers, 3.5-5.5% (w/v) a first macromolecule having a molecular weight of 40-100 KDa, and an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to 2.0-3.0.

A normothermic perfusion circuit can be used to perfuse a donor heart after transportation and before transplantation. The circuit can drain the organ storage container of cold preservation solution, perfuse the aorta of the heart with warm fluid to initiate heart activity, and then perfuse the left atrium of the heart with warm fluid to bolster heart activity and evaluate heart viability. Heart viability can be determined using parameters measured by sensors in the circuit.

A normothermic perfusion circuit can be used to perfuse a donor heart after transportation and before transplantation. The circuit can drain the organ storage container of cold preservation solution, perfuse the aorta of the heart with warm fluid to initiate heart activity, and then perfuse the left atrium of the heart with warm fluid to bolster heart activity and evaluate heart viability. Heart viability can be determined using parameters measured by sensors in the circuit.

The present disclosure provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: dimethyl sulfoxide (DMSO), disaccharide, human serum, and IL-7 and/or IL-15. The present disclosure also provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: between about 1 w/v % and 10 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and between about 10 w/v % and 90 w/v % human serum. The present disclosure also provides, among other things, a cryopreservation medium for cryopreserving mammalian cells, the medium comprising: between about 1 w/v % and 10 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and between about 0.5 w/v % and 30 w/v % human serum albumin.